There are 2789 resources available
613P - Chromosomal instability (CIN) biomarker in circulating tumor cells (CTC) may predict for therapy resistance in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Niamh Keegan
Session: ePoster Display
536P - Incidence of fractures in TRK fusion cancer patients treated with larotrectinib
Presenter: Theodore W. Laetsch
Session: ePoster Display
537P - Exposure-response analysis of cabozantinib in patients with metastatic renal cell cancer treated in routine care
Presenter: Stefanie Krens
Session: ePoster Display
539P - Interim results of a phase I study of M701, a recombinant anti-EpCAM and anti-CD3 bispecific antibody in EpCAM-positive cancer patients with malignant ascites
Presenter: Jianming Xu
Session: ePoster Display
540P - Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor and an affinity optimized TCR targeting MAGE-A4
Presenter: David Hong
Session: ePoster Display
620P - MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion
Presenter: Eugene Shenderov
Session: ePoster Display
621P - Efficacy and safety of relugolix vs leuprolide (LEU) in men with advanced prostate cancer (APC): Clinical subgroup analysis from the phase III HERO study
Presenter: Bertrand Tombal
Session: ePoster Display
622P - Geographical assessment of efficacy and safety of relugolix: A subgroup analysis from the randomized, phase III HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC)
Presenter: Bertrand Tombal
Session: ePoster Display
623P - Real-world treatment patterns in metastatic hormone-sensitive prostate cancer (mHSPC) patients in the US, Germany, France, China and Japan
Presenter: Peter Goebell
Session: ePoster Display